# Dose-effect of SSR180575 in Diabetic Neuropathy

> **NCT00502515** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 309 (actual)

## Conditions studied

- Diabetic Neuropathies

## Interventions

- **DRUG:** SSR180575
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00502515
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502515, "Dose-effect of SSR180575 in Diabetic Neuropathy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00502515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*